Similar conclusions may be extended to the clinical use of fulvestrant as a treatment for PCa, taking into consideration that, in addition to ERα, inhibition of ERβ and agonistic activity at GPER were demonstrated as well [69,220,221]. This evidence concerns the gene ESR2 and posterior cortical atrophy.